Accéder au contenu
Merck

Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells.

The Journal of experimental medicine (2005-06-09)
Niklas Feldhahn, Florian Klein, Jana L Mooster, Paul Hadweh, Mieke Sprangers, Maria Wartenberg, Mohamed M Bekhite, Wolf-Karsten Hofmann, Sebastian Herzog, Hassan Jumaa, Janet D Rowley, Markus Müschen
RÉSUMÉ

Pre-B cells undergo apoptosis unless they are rescued by pre-B cell receptor-dependent survival signals. We previously showed that the BCR-ABL1 kinase that is expressed in pre-B lymphoblastic leukemia bypasses selection for pre-B cell receptor-dependent survival signals. Investigating possible interference of BCR-ABL1 with pre-B cell receptor signaling, we found that neither SYK nor SLP65 can be phosphorylated in response to pre-B cell receptor engagement. Instead, Bruton's tyrosine kinase (BTK) is constitutively phosphorylated by BCR-ABL1. Activated BTK is essential for survival signals that otherwise would arise from the pre-B cell receptor, including activation of PLCgamma1, autonomous Ca2+ signaling, STAT5-phosphorylation, and up-regulation of BCLX(L). Inhibition of BTK activity specifically induces apoptosis in BCR-ABL1+ leukemia cells to a similar extent as inhibition of BCR-ABL1 kinase activity itself. However, BCR-ABL1 cannot directly bind to full-length BTK. Instead, BCR-ABL1 induces the expression of a truncated splice variant of BTK that acts as a linker between the two kinases. As opposed to full-length BTK, truncated BTK lacks kinase activity yet can bind to BCR-ABL1 through its SRC-homology domain 3. Acting as a linker, truncated BTK enables BCR-ABL1-dependent activation of full-length BTK, which initiates downstream survival signals and mimics a constitutively active pre-B cell receptor.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
LFM-A13, ≥98% (HPLC), powder
Sigma-Aldrich
BTK active human, recombinant, expressed in baculovirus infected Sf9 cells, ≥80% (SDS-PAGE)